Updated:
R42 Group
R42 Group traces to 2004 when Dr. Ronjon Nag converted proceeds from his prior company sales into a dedicated investment vehicle. The structure combines...
R42 Group
R42 Group traces to 2004 when Dr. Ronjon Nag converted proceeds from his prior company sales into a dedicated investment vehicle. The structure combines family-office capital allocation with a venture fund and an institute that runs lectures and academic programs. R42 invests in AI, biotechnology and fintech. It commits to early-stage funds and executes direct co-investments alongside those funds. Confirmed activity spans seed and growth rounds across North America and Europe. Portfolio positions include companies developing AI drug-discovery platforms, blood-brain-barrier therapeutics and smart-city infrastructure. The office maintains a small principal team and draws on external scientific advisors. Dr. Nag holds an adjunct faculty appointment at Stanford and serves on boards including MIT Alumni Angels of Northern California and the Institution of Engineering and Technology. No material operational events have been recorded in the last 24 months.
General information
Firm type
Single Family Office
Year founded
2004
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Principals
Anastasiya Giarletta
Principal
Artem Trotsyuk
Principal
Sector focus
Frequently asked questions
Who runs investment decisions at R42 Group?
Dr. Ronjon Nag sets overall direction. Principals Anastasiya Giarletta and Artem Trotsyuk manage day-to-day deal flow and portfolio support.
Does R42 Group participate in fund commitments or only direct deals?
R42 invests as an LP in aligned early-stage funds and co-invests directly into select companies alongside those funds.
What investment stages does R42 Group typically target?
The firm leads at the pre-seed and seed stages and continues to support companies through growth rounds.
Where does the underlying wealth come from?
Capital originates from Dr. Ronjon Nag's prior exits of speech-recognition and mobile-platform companies to Motorola, BlackBerry and Apple.
How does R42 Group source proprietary deal flow?
Sourcing occurs through Dr. Nag's academic network at Stanford, angel-group affiliations and direct outreach to scientific founders.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: